<DOC>
	<DOCNO>NCT02111590</DOCNO>
	<brief_summary>The aim study evaluate development hemolysis variation isokinetic muscle strength two group patient chronic inflammatory demyelinate polyneuropathy ( CIDP ) multifocal motor neuropathy ( MMN ) 1 . Patients shift 3- 6-weekly treatment intravenous immunoglobulin ( IVIG ) weekly treatment subcutanoeus immunoglobulin ( SCIG ) 2 . Patients shift SCIG treatment Subcuvia® Hizentra® Gammanorm® . Hypotheses - During treatment IVIG blood hemoglobin fluctuate decline due infusion , whereas remain stable SCIG treatment without fluctuation - Isokinetic muscle strength affect muscle group stable treatment SCIG IVIG - Blood hemoglobin change muscle strength comparable Subcuvia® Hizentra® Gammanorm® treatment</brief_summary>
	<brief_title>Immunoglobulin Dosage Administration Form CIDP MMN</brief_title>
	<detailed_description>Due plan switch treatment immunoglobulin Department neurology ( Rigshospitalet ) patient treat IVIG shift treatment SCIG unaltered dosage . The medication administer home two three time weekly . IVIG often administer every 3 6 week . All patient train manage treatment SCIG nurse neurological department . When patient able manage treatment regimen do home . All patient evaluate eight time study period . Four time four time shift treatment . Prior participation interval standardize 3 6 week give extra infusion interval 3 week , i.e . patient 4-week interval switch 3-week interval patient 5-week interval switch 6-week interval . The dose adjust lead unchanged weekly dose IVIG . All patient evaluate connection two IVIG infusion . For receive 3 infusion examination execute 2 week first last infusion . SCIG initiate 2 week last IVIG infusion . Patients maintenance therapy Subcuvia® Hizentra® shift treatment Gammanorm® accord guideline Danish Healthcare Society , weekly dose immunoglobulin unaltered . They evaluate 3 time ( , time shift SCIG ) . All evaluation time point group consist measurement isokinetic muscle strength four affected muscle group blood sample detect blood hemoglobin hemolytic parameter .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosed CIDP MMN fulfil EFNS/PNS criterion Maintenance treatment IVIG SCIG least 3 month Negative result pregnancy test ( HCGbased assay urine ) woman childbearing potential use reliable method contraception duration study Pure sensory severe ataxic CIDP Other cause neuropathy ( incl . pressure neuropathy ) Known history adverse reaction IgA product Exposure blood blood product plasma derivative , Privigen , within past 3 month prior first infusion Gammanorm Ongoing history hypersensitivity persistent reaction blood plasma derive product . Requirement routine premedication IgG administration History malignancy lymphoid cell immunodeficiency lymphoma Severe liver function impairment ( ALAT 3 time upper limit normal ) Known proteinlosing enteropathy proteinuria . Live viral vaccination ( measles , rubella , mumps varicella ) within last 2 month prior first infusion Gammanorm Treatment investigational medicinal product within 3 month prior first infusion Gammanorm Medication interfere hematopoiesis Other immunomodulation therapy low dose steroid ( Prednisolone &lt; 25 mg daily ) Known suspect abuse alcohol , drug , psychotropic agent chemical within past 12 month prior first infusion Gammanorm Known suspect HIV , HCV , HBV infection Pregnant nursing woman Planned pregnancy course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Immunoglobulins , Subcutaneous</keyword>
</DOC>